Natco Pharma plans to step up focus on high potential filings and differentiated products in the complex generics segment for exports as part of its growth strategy.

“The focus will be on a few high-potential filings predominantly differentiated products through either novel drug delivery systems or complex chemistries,’’ Hyderabad-based Natco said in an investor presentation.

Apart from pushing growth through subsidiaries, Nacto sees advantage from its growing presence in new markets in the Rest of the World (RoW) led by hepatitis C franchise products.

In Canada, it launched Oseltamivir (generic drug of Tamiflu) and obtained 12 approvals and successful listings in major provinces and retail chains.

In Brazil, where it stared operations in 2011, filed multiple oncology products.

In Europe, it forged distribution arrangements to sell products in eastern Europe, the UK and Germany. It had recently launched niche molecules in the US market, including Liposomal Doxorubicin, Glatiramer Acetate and suspension version of Oseltamivir.

In the domestic formulations space, Natco hopes to maintain leadership position in oncology and hepatitis C segments.

In the near term, it has lined up eight to 10 products and strengthen newly launched Cardiology and Diabetology (CnD) division.

Since its launch in early 2017, Natco had launched Argatroban injection for treatment of patients with thrombosis syndrome.

“The focus will be on niche molecules with high entry barriers,’’ it said.

In the long term, it may take up the acquisition route as it hints at “growth through inorganic strategies’’.

Consolidated profit zooms Natco Pharma’s consolidated net profit increased 27.5 per cent at ₹84.4 crore in the second quarter ended September 30, 2017, against ₹66.2 crore in the year-ago period on a revenue of ₹432 crore (₹471 crore).

On Tuesday, its scrip remained flat at ₹927.80 on the BSE.

Related Topics